Discontinuation Rate of Lurasidone and Quetiapine Extended Release in Bipolar Depression.

IF 3.6 3区医学 Q2 PHARMACOLOGY & PHARMACY

Pharmacopsychiatry Pub Date : 2024-09-01 Epub Date: 2024-06-19 DOI:10.1055/a-2331-2300

Taro Kishi, Kenji Sakuma, Shun Hamanaka, Yasufumi Nishii, Nakao Iwata

{"title":"Discontinuation Rate of Lurasidone and Quetiapine Extended Release in Bipolar Depression.","authors":"Taro Kishi, Kenji Sakuma, Shun Hamanaka, Yasufumi Nishii, Nakao Iwata","doi":"10.1055/a-2331-2300","DOIUrl":null,"url":null,"abstract":"Introduction: Lurasidone (LUR) was compared with quetiapine extended release (QUE-ER) regarding 1-year discontinuation in patients with bipolar depression (n=317).Methods: This is a retrospective cohort study.Results: Although the time to all-cause discontinuation was estimated using the Kaplan-Meier survival curve with log-rank tests to compare treatment groups, no difference was found (p=0.317). The Cox proportional hazard model revealed that only the presence of adverse events (AEs) is associated with increased treatment discontinuation (p<0.0001). The most common AEs were akathisia for LUR (17.7%) and somnolence for QUE-ER (34.7%). In other Cox models divided by LUR or QUE-ER, the presence of akathisia or somnolence was associated with increased LUR (p=0.0205) or QUE-ER (p<0.0001) discontinuation, respectively.Discussion: The acceptability of both antipsychotics to bipolar depression in clinical practice may be similar. However, specific AEs for each antipsychotic (LUR: akathisia and QUE-ER: somnolence) were associated with high treatment discontinuation.","PeriodicalId":19783,"journal":{"name":"Pharmacopsychiatry","volume":" ","pages":"245-248"},"PeriodicalIF":3.6000,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmacopsychiatry","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1055/a-2331-2300","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/6/19 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Lurasidone (LUR) was compared with quetiapine extended release (QUE-ER) regarding 1-year discontinuation in patients with bipolar depression (n=317).

Methods: This is a retrospective cohort study.

Results: Although the time to all-cause discontinuation was estimated using the Kaplan-Meier survival curve with log-rank tests to compare treatment groups, no difference was found (p=0.317). The Cox proportional hazard model revealed that only the presence of adverse events (AEs) is associated with increased treatment discontinuation (p<0.0001). The most common AEs were akathisia for LUR (17.7%) and somnolence for QUE-ER (34.7%). In other Cox models divided by LUR or QUE-ER, the presence of akathisia or somnolence was associated with increased LUR (p=0.0205) or QUE-ER (p<0.0001) discontinuation, respectively.

Discussion: The acceptability of both antipsychotics to bipolar depression in clinical practice may be similar. However, specific AEs for each antipsychotic (LUR: akathisia and QUE-ER: somnolence) were associated with high treatment discontinuation.

查看原文本刊更多论文

鲁拉西酮和喹硫平缓释剂在双相抑郁症中的停药率。

简介：研究比较了鲁拉西酮（LUR）与喹硫平缓释片（QUE-ER）对双相抑郁症患者（n=317）1年停药情况：方法：这是一项回顾性队列研究：这是一项回顾性队列研究：尽管使用卡普兰-梅耶生存曲线估算了全因停药时间，并用对数秩检验比较了治疗组，但没有发现差异（P=0.317）。考克斯比例危险模型显示，只有出现不良事件（AEs）才与治疗中断率增加有关（P=0.317）：两种抗精神病药物在临床实践中对双相抑郁症的可接受性可能相似。然而，每种抗精神病药物的特定 AE（LUR：肌无力和 QUE-ER：嗜睡）都与治疗中断率高有关。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Pharmacopsychiatry 医学-精神病学

CiteScore

7.10

自引率

9.30%

发文量

审稿时长

6-12 weeks

期刊介绍： Covering advances in the fi eld of psychotropic drugs, Pharmaco psychiatry provides psychiatrists, neuroscientists and clinicians with key clinical insights and describes new avenues of research and treatment. The pharmacological and neurobiological bases of psychiatric disorders are discussed by presenting clinical and experimental research.